USA flag logo/image

An Official Website of the United States Government

li-Key/Melanoma MHC Class II Vaccines

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65475
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
CA103390
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ANTIGEN EXPRESS, INC.
ANTIGEN EXPRESS, INC. 100 BARBER AVE WORCESTER, MA 01606
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: li-Key/Melanoma MHC Class II Vaccines
Agency: HHS
Contract: 1R43CA103390-01
Award Amount: $444,070.00
 

Abstract:

DESCRIPTION (provided by applicant): MHC-presented peptide vaccines are one of the most promising experimental therapies for melanoma. However, MHC class I peptides that prime CTLs lack dramatic anti-tumor effect in clinical trials. Co-immunization with MHC class II peptides substantially enhances CTL potency, augments antibody development and provides memory. A drawback to this approach is that MHC class II epitope bind poorly, therefore they are weak immunogens. Antigen Express scientists found that coupling the li-Key segment of the immunoregulatory li-protein to the N-terminus of a MHC class II epitope enhances the potency of class II epitope peptide presentation 200 times more than the epitope-only peptide. Our studies in immunized mice demonstrate 4-6 fold enhancement of Th1 cells by with li-Key/MHC II hybrid as measured by ELISPOT. In vitro li-Key/HER-21/neu(MHC II epitope) hybrids potently stimulate peripheral blood or draining lymph node lymphocytes from breast cancer patients. Applying these methods to melanoma, we will define the most potent HLA-DR-restricted li-Key/tyrosinase(MHC II) and li-key/gpl00(MHC II) hybrids for a clinical trial by our collaborator, Dr. Jedd Wolchok of Memorial Sloan Kettering Cancer Center (MSKCC). He will use these MHC class II hybrids to potentiate CTL and clinical responses to previously used tyrosinase and gp100 HLA-A2-restricted CTL epitope peptide vaccines. Here we will define the optimal sequence of MHC class II epitopes for incorporation in new hybrids, optimal spacer length, and dose/dosage and immune response parameters in mice. In parallel with studies using human cells in vitro, Dr. MigueI-Angel Perales from MSKCC will confirm our structure-activity findings. Toxicology studies in mice and rabbits of one GMP batch of the optimal peptide(s) will complete our preclinical studies of this SBIR, supporting a clinical trial at Memorial Sloan-Kettering.

Principal Investigator:

Minzhen Xu
5088528783
ANTIGENEXP@AOL.COM

Business Contact:

Robert Humphreys
5088528801
ANTIGENEXP@AOL.COM
Small Business Information at Submission:

ANTIGEN EXPRESS, INC.
ANTIGEN EXPRESS, INC. 100 BARBER AVE WORCESTER, MA 01606

EIN/Tax ID: 043208418
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No